Drug intelligence / Profile preview

WRAIR-PAM-CF1

Development stage: Phase 2
Lead developer: BiomX, Inc.
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous

Overview

**WRAIR-PAM-CF1** is an investigational intravenous, four-component lytic bacteriophage cocktail developed to reduce *Pseudomonas aeruginosa* burden in adults with cystic fibrosis who are chronically colonized with the pathogen. The product comprises PaWRA01Phi11, PaWRA01Phi39, PaWRA02Phi83, and PaWRA02Phi87, naturally occurring phages that infect and lyse *P. aeruginosa*. It is being evaluated in the NIAID-sponsored PHAGE study, a randomized Phase 1b/2 trial assessing single-dose safety and microbiological activity. ([cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/78/NCT05453578/Prot_001.pdf))

Other names: Walter Reed Army Institute of Research-PAM-Cystic Fibrosis1

Targets

P. aeruginosa (Pseudomonas aeruginosa)

Beyond the preview

Go deeper on WRAIR-PAM-CF1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WRAIR-PAM-CF1.

Explore the full profile